TY - JOUR
T1 - Age-related modulation of plasmatic beta-Galactosidase activity in healthy subjects and in patients affected by T2DM
AU - Spazzafumo, Liana
AU - Mensà, Emanuela
AU - Matacchione, Giulia
AU - Galeazzi, Tiziana
AU - Zampini, Lucia
AU - Recchioni, Rina
AU - Marcheselli, Fiorella
AU - Prattichizzo, Francesco
AU - Testa, Roberto
AU - Antonicelli, Roberto
AU - Garagnani, Paolo
AU - Boemi, Massimo
AU - Bonafè, Massimiliano
AU - Bonfigli, Anna Rita
AU - Procopio, Antonio Domenico
AU - Olivieri, Fabiola
PY - 2017/11/7
Y1 - 2017/11/7
N2 - β-Galactosidase (β-Gal) activity has been the most extensively utilized biomarker for the detection of cellular senescence. It can be measured also in plasma, and few recent evidence showed an altered plasmatic β-Gal activity in patients affected by some age-related diseases (ARDs). Since T2DM is one of the most common ARDs, we aimed to investigate if plasmatic β-Gal activity is modulated in T2DM patients and if "age" could affect such modulation. To gain mechanistic insights we paralleled this investigation with the evaluation of β-Gal activity in young and senescent endothelial cells (HUVECs) cultured in normo- and hyper-glycaemic environment. A significant age-related increase of plasmatic β-Gal activity was observed in healthy subjects (n. 230; 55-87 years), whereas the enzymatic activity was significantly reduced in T2DM patients (n. 230; 55-96 years) compared to healthy subjects. β-Gal activity detectable both in cells and in the culture medium was significantly increased in senescent cells compared to the younger ones, both under normo- and hyper-glycaemic condition. However, the hyper-glycaemic condition was not associated with an increased β-Gal activity in milieu compared to normo-glycaemic condition. Overall our data reinforce the notion that plasmatic β-Gal activity could be a systemic biomarker of aging, whereas T2DM patients are characterized by a different age-releated trend.
AB - β-Galactosidase (β-Gal) activity has been the most extensively utilized biomarker for the detection of cellular senescence. It can be measured also in plasma, and few recent evidence showed an altered plasmatic β-Gal activity in patients affected by some age-related diseases (ARDs). Since T2DM is one of the most common ARDs, we aimed to investigate if plasmatic β-Gal activity is modulated in T2DM patients and if "age" could affect such modulation. To gain mechanistic insights we paralleled this investigation with the evaluation of β-Gal activity in young and senescent endothelial cells (HUVECs) cultured in normo- and hyper-glycaemic environment. A significant age-related increase of plasmatic β-Gal activity was observed in healthy subjects (n. 230; 55-87 years), whereas the enzymatic activity was significantly reduced in T2DM patients (n. 230; 55-96 years) compared to healthy subjects. β-Gal activity detectable both in cells and in the culture medium was significantly increased in senescent cells compared to the younger ones, both under normo- and hyper-glycaemic condition. However, the hyper-glycaemic condition was not associated with an increased β-Gal activity in milieu compared to normo-glycaemic condition. Overall our data reinforce the notion that plasmatic β-Gal activity could be a systemic biomarker of aging, whereas T2DM patients are characterized by a different age-releated trend.
KW - Journal Article
U2 - 10.18632/oncotarget.21848
DO - 10.18632/oncotarget.21848
M3 - Article
C2 - 29212153
VL - 8
SP - 93338
EP - 93348
JO - Oncotarget
JF - Oncotarget
SN - 1949-2553
IS - 55
ER -